Literature DB >> 11565810

Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin.

M A Ghert1, W N Qi, H P Erickson, J A Block, S P Scully.   

Abstract

Tenascin-C is an oligomeric glycoprotein of the extracellular matrix that has been found to have both adhesive and anti-adhesive properties for cells. Recent elucidation of the two major TNC splice variants (320 kDa and 220 kDa) has shed light on the possibility of varying functions of the molecule based on its splicing pattern. Tenascin-C is prominently expressed in embryogenesis and in pathologic conditions such as tumorogenesis and wound healing. Fibronectin is a prominent adhesive molecule of the extracellular matrix that is often co-localized with tenascin-C in these processes. We studied the chondrosarcoma cell line JJ012 with enzyme-linked immunoabsorbance assays, cell attachment assays and antibody-blocking assays to determine the adhesive/anti-adhesive properties of the two major tenascin-C splice variants with respect to fibronectin and their effect on chondrosarcoma cell attachment. We found that the small tenascin-C splice variant (220 kDa) binds to fibronectin, whereas the large tenascin-C splice variant (320 kDa) does not. In addition, the small tenascin-C splice variant was found to decrease adhesion for cells when bound to fibronectin, but contributed to adhesion when bound to plastic in fibronectin-coated wells. Antibody blocking experiments confirmed that both the small tenascin-C splice variant and fibronectin contribute to cell adhesion when bound to plastic. The large tenascin-C splice variant did not promote specific cell attachment. We hypothesize that the biologic activity of tenascin-C is dependent on the tissue-specific splicing pattern. The smaller tenascin-C isoform likely plays a structural and adhesive role, whereas the larger isoform, preferentially expressed in malignant tissue, likely plays a role in cell egress and metastasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565810     DOI: 10.1247/csf.26.179

Source DB:  PubMed          Journal:  Cell Struct Funct        ISSN: 0386-7196            Impact factor:   2.212


  14 in total

1.  A thin-layer model for viscoelastic, stress-relaxation testing of cells using atomic force microscopy: do cell properties reflect metastatic potential?

Authors:  Eric M Darling; Stefan Zauscher; Joel A Block; Farshid Guilak
Journal:  Biophys J       Date:  2006-12-08       Impact factor: 4.033

Review 2.  Extracellular matrix in the trabecular meshwork.

Authors:  Ted S Acott; Mary J Kelley
Journal:  Exp Eye Res       Date:  2008-01-25       Impact factor: 3.467

3.  Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin.

Authors:  Wing S To; Kim S Midwood
Journal:  J Biol Chem       Date:  2011-02-15       Impact factor: 5.157

4.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

5.  A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Authors:  Alexander Berndt; Robert Köllner; Petra Richter; Marcus Franz; Astrid Voigt; Angela Berndt; Laura Borsi; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

6.  Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages.

Authors:  Anna M Piccinini; Lorena Zuliani-Alvarez; Jenny M P Lim; Kim S Midwood
Journal:  Sci Signal       Date:  2016-08-30       Impact factor: 8.192

7.  Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Authors:  David S Guttery; Rachael A Hancox; Kellie T Mulligan; Simon Hughes; Sinead M Lambe; J Howard Pringle; Rosemary A Walker; J Louise Jones; Jacqueline A Shaw
Journal:  Breast Cancer Res       Date:  2010-08-02       Impact factor: 6.466

8.  Phylogenetic analysis of the tenascin gene family: evidence of origin early in the chordate lineage.

Authors:  R P Tucker; K Drabikowski; J F Hess; J Ferralli; R Chiquet-Ehrismann; J C Adams
Journal:  BMC Evol Biol       Date:  2006-08-07       Impact factor: 3.260

9.  Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).

Authors:  R De Santis; A M Anastasi; V D'Alessio; A Pelliccia; C Albertoni; A Rosi; B Leoni; R Lindstedt; F Petronzelli; M Dani; A Verdoliva; A Ippolito; N Campanile; V Manfredi; A Esposito; G Cassani; M Chinol; G Paganelli; P Carminati
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

Review 10.  Tenascin-C: Form versus function.

Authors:  Sean P Giblin; Kim S Midwood
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.